CTLA4 and melanoma: 45 patients with unresectable, late‐stage, malignant melanoma were recruited, of which 60% were about to begin anti‐CTLA‐4, 24% anti‐PD‐1, and 16% anti‐CTLA‐4/PD‐1 combination therapy (Table 1).